EcoR1 Capital — 2020 Investments
2 investments dated 2020 · listed companies and verified rows first · show all
BiotechNew York, US
Norbert Bischofberger, Ph.D.(Executive Officer, Director)Christopher Wilfong(Executive Officer)
BoardRebecka Belldegrun, M.D.(Director)Otello Stampacchia, Ph.D.(Director)David M. Tanen(Executive Officer, Director, Promoter)Arie S. Belldegrun, M.D.(Director)
Co-investorsGV (Google Ventures)Nextech InvestVida VenturesBlackRockCommodore CapitalInvus+1 more
Clinical-stage biotech developing neoantigen-targeted T cell receptor (TCR) therapies for cancer; acquired by AstraZeneca.
BiotechNew York, US
Carsten Linnemann, PhD(Executive Officer, Director, Promoter)Antonius N.M. Schumacher(Director)Fei Chen(Director)
BoardDavid M. Tanen(Director, Promoter)Helen Kim(Director)
Co-investorsJeito CapitalVida VenturesTPG
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.